Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any nephronophthisis in which the cause of the disease is a mutation in the CEP164 gene.
Features include very common findings: Nephronophthisis and Retinal degeneration; and sometimes findings: Cerebellar vermis hypoplasia, Nystagmus, Seizure, and Global developmental delay and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 3 | Nystagmus, Blindness, Retinal degeneration |
CEP164 encodes centrosomal protein 164 (1,460 aa). Plays a role in microtubule organization and/or maintenance for the formation of primary cilia (PC), a microtubule-based structure that protrudes from the surface of epithelial cells. Highest expression in Testis (59.4 TPM) and Brain Cerebellum (33.9 TPM).
Nephronophthisis 15 is associated with mutations in the CEP164 gene on chromosome 11.
The CEP164 protein participates in CEP164 recruits RAB3IP-carrying Golgi-derived vesicles to the basal body, PDE6D dissociates from ARL13B:INPP5E, and INPP5E translocates to the primary cilium pathways.
CEP164 is classified as a druggable target (Dna Repair category) with score 0.0.
Genetic testing for CEP164 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 2 very common features.
No clinical trials have been registered for nephronophthisis 15.
11 publications have been identified in PubMed for nephronophthisis 15. Research spans Case Report / Case Series (36%), Basic Science / Preclinical (36%), and Review / Meta-Analysis (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 4 | 36% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:43 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
2 |
Seizure, Global developmental delay |
Kidneys and urinary system | 1 | Nephronophthisis |
Digestive system | 1 | Elevated circulating hepatic transaminase concentration |
Lab test results | 1 | Elevated circulating hepatic transaminase concentration |
4 |
36% |
Research summaries | 2 | 18% |
Disease patterns and progression | 1 | 9% |
Sy PM (2026). [PMID: 42215835](https://pubmed.ncbi.nlm.nih.gov/42215835/). *CEN Case Rep*. [Case Report / Case Series]
Li M (2026). [PMID: 41827476](https://pubmed.ncbi.nlm.nih.gov/41827476/). *Journal of clinical medicine*. [Case Report / Case Series]
Clince M (2026). [PMID: 41565023](https://pubmed.ncbi.nlm.nih.gov/41565023/). *Kidney international*. [Epidemiology / Natural History]
Suzuki T (2025). [PMID: 40968381](https://pubmed.ncbi.nlm.nih.gov/40968381/). *Stem cell research & therapy*. [Basic Science / Preclinical]
Zhou D (2025). [PMID: 40427560](https://pubmed.ncbi.nlm.nih.gov/40427560/). *Biomolecules*. [Review / Meta-Analysis]
Eckert P (2025). [PMID: 40806500](https://pubmed.ncbi.nlm.nih.gov/40806500/). *International journal of molecular sciences*. [Basic Science / Preclinical]
Matsuo T (2025). [PMID: 40503542](https://pubmed.ncbi.nlm.nih.gov/40503542/). *Journal of medical cases*. [Case Report / Case Series]
Yang Y (2025). [PMID: 39995111](https://pubmed.ncbi.nlm.nih.gov/39995111/). *Clinical and translational medicine*. [Basic Science / Preclinical]
Almohlesy LS (2024). [PMID: 39596574](https://pubmed.ncbi.nlm.nih.gov/39596574/). *Genes*. [Case Report / Case Series]
Kuwasako K (2024). [PMID: 38551798](https://pubmed.ncbi.nlm.nih.gov/38551798/). *Biomolecular NMR assignments*. [Basic Science / Preclinical]